172 related articles for article (PubMed ID: 35914182)
1. Efficacy of ensitrelvir against SARS-CoV-2 in a delayed-treatment mouse model.
Nobori H; Fukao K; Kuroda T; Anan N; Tashima R; Nakashima M; Noda S; Tajiri M; Torii M; Toba S; Uemura K; Sanaki T; Shishido T; Tachibana Y; Kato T
J Antimicrob Chemother; 2022 Oct; 77(11):2984-2991. PubMed ID: 35914182
[TBL] [Abstract][Full Text] [Related]
2. Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo.
Kuroda T; Nobori H; Fukao K; Baba K; Matsumoto K; Yoshida S; Tanaka Y; Watari R; Oka R; Kasai Y; Inoue K; Kawashima S; Shimba A; Hayasaki-Kajiwara Y; Tanimura M; Zhang Q; Tachibana Y; Kato T; Shishido T
J Antimicrob Chemother; 2023 Apr; 78(4):946-952. PubMed ID: 36760083
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and Pharmacodynamic Analysis of the 3CL Protease Inhibitor Ensitrelvir in a SARS-CoV-2 Infection Mouse Model.
Fukao K; Nobori H; Kuroda T; Baba K; Matsumoto K; Tanaka Y; Tachibana Y; Kato T; Shishido T
Viruses; 2023 Oct; 15(10):. PubMed ID: 37896829
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic effect of ensitrelvir in mice infected with SARS-CoV-2.
Nobori H; Baba K; Kuroda T; Baba K; Matsumoto K; Yoshida S; Watari R; Tachibana Y; Kato T; Fukao K
Antiviral Res; 2024 Apr; 224():105852. PubMed ID: 38428748
[TBL] [Abstract][Full Text] [Related]
5. A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part.
Mukae H; Yotsuyanagi H; Ohmagari N; Doi Y; Imamura T; Sonoyama T; Fukuhara T; Ichihashi G; Sanaki T; Baba K; Takeda Y; Tsuge Y; Uehara T
Antimicrob Agents Chemother; 2022 Oct; 66(10):e0069722. PubMed ID: 36098519
[TBL] [Abstract][Full Text] [Related]
6. Ensitrelvir as a potential treatment for COVID-19.
McCarthy MW
Expert Opin Pharmacother; 2022 Dec; 23(18):1995-1998. PubMed ID: 36350029
[TBL] [Abstract][Full Text] [Related]
7. Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally.
Kawashima S; Matsui Y; Adachi T; Morikawa Y; Inoue K; Takebayashi S; Nobori H; Rokushima M; Tachibana Y; Kato T
Biochem Biophys Res Commun; 2023 Feb; 645():132-136. PubMed ID: 36689809
[TBL] [Abstract][Full Text] [Related]
8. Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults.
Shimizu R; Sonoyama T; Fukuhara T; Kuwata A; Matsuo Y; Kubota R
Antimicrob Agents Chemother; 2022 Oct; 66(10):e0063222. PubMed ID: 36094202
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study.
Mukae H; Yotsuyanagi H; Ohmagari N; Doi Y; Sakaguchi H; Sonoyama T; Ichihashi G; Sanaki T; Baba K; Tsuge Y; Uehara T
Clin Infect Dis; 2023 Apr; 76(8):1403-1411. PubMed ID: 36477182
[TBL] [Abstract][Full Text] [Related]
10. A phase 2/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 part).
Yotsuyanagi H; Ohmagari N; Doi Y; Imamura T; Sonoyama T; Ichihashi G; Sanaki T; Tsuge Y; Uehara T; Mukae H
Medicine (Baltimore); 2023 Feb; 102(8):e33024. PubMed ID: 36827007
[TBL] [Abstract][Full Text] [Related]
11. A SCID Mouse Model To Evaluate the Efficacy of Antivirals against SARS-CoV-2 Infection.
Abdelnabi R; Foo CS; Kaptein SJF; Boudewijns R; Vangeel L; De Jonghe S; Jochmans D; Weynand B; Neyts J
J Virol; 2022 Aug; 96(16):e0075822. PubMed ID: 35924921
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir.
Kiso M; Yamayoshi S; Iida S; Furusawa Y; Hirata Y; Uraki R; Imai M; Suzuki T; Kawaoka Y
Nat Commun; 2023 Jul; 14(1):4231. PubMed ID: 37454219
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Ensitrelvir for Asymptomatic or Mild COVID-19: An Exploratory Analysis of a Multicenter, Randomized, Phase 2b/3 Clinical Trial.
Ohmagari N; Yotsuyanagi H; Doi Y; Yamato M; Imamura T; Sakaguchi H; Yamanaka H; Imaoka R; Fukushi A; Ichihashi G; Sanaki T; Tsuge Y; Uehara T; Mukae H
Influenza Other Respir Viruses; 2024 Jun; 18(6):e13338. PubMed ID: 38890511
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy with oral antiviral and anti-inflammatory drugs improves the efficacy of delayed treatment in a COVID-19 hamster model.
Sasaki M; Sugi T; Iida S; Hirata Y; Kusakabe S; Konishi K; Itakura Y; Tabata K; Kishimoto M; Kobayashi H; Ariizumi T; Intaruck K; Nobori H; Toba S; Sato A; Matsuno K; Yamagishi J; Suzuki T; Hall WW; Orba Y; Sawa H
EBioMedicine; 2024 Jan; 99():104950. PubMed ID: 38159532
[TBL] [Abstract][Full Text] [Related]
15. Cytokines and Lipid Mediators of Inflammation in Lungs of SARS-CoV-2 Infected Mice.
Dubuc I; Prunier J; Lacasse É; Gravel A; Puhm F; Allaeys I; Archambault AS; Gudimard L; Villano R; Droit A; Flamand N; Boilard É; Flamand L
Front Immunol; 2022; 13():893792. PubMed ID: 35812400
[TBL] [Abstract][Full Text] [Related]
16. Sporadic Occurrence of Ensitrelvir-Resistant SARS-CoV-2, Japan.
Doi A; Ota M; Saito M; Matsuyama S
Emerg Infect Dis; 2024 Jun; 30(6):1289-1291. PubMed ID: 38669127
[TBL] [Abstract][Full Text] [Related]
17. S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters.
Sasaki M; Tabata K; Kishimoto M; Itakura Y; Kobayashi H; Ariizumi T; Uemura K; Toba S; Kusakabe S; Maruyama Y; Iida S; Nakajima N; Suzuki T; Yoshida S; Nobori H; Sanaki T; Kato T; Shishido T; Hall WW; Orba Y; Sato A; Sawa H
Sci Transl Med; 2023 Jan; 15(679):eabq4064. PubMed ID: 36327352
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of deuterated S-217622 (Ensitrelvir) with antiviral activity against coronaviruses including SARS-CoV-2.
Yang Y; Cao L; Yan M; Zhou J; Yang S; Xu T; Huang S; Li K; Zhou Q; Li G; Zhu Y; Cong F; Zhang H; Guo D; Li Y; Zhang X
Antiviral Res; 2023 May; 213():105586. PubMed ID: 36997073
[TBL] [Abstract][Full Text] [Related]
19. Antiviral and Anti-Inflammatory Activities of Fluoxetine in a SARS-CoV-2 Infection Mouse Model.
Péricat D; Leon-Icaza SA; Sanchez Rico M; Mühle C; Zoicas I; Schumacher F; Planès R; Mazars R; Gros G; Carpinteiro A; Becker KA; Izopet J; Strub-Wourgaft N; Sjö P; Neyrolles O; Kleuser B; Limosin F; Gulbins E; Kornhuber J; Meunier E; Hoertel N; Cougoule C
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362409
[TBL] [Abstract][Full Text] [Related]
20. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
Li K; Meyerholz DK; Bartlett JA; McCray PB
mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]